Drug Trial Radar · NCT07393659
A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
197
Planned (sponsor's estimate)
Start
Jul 21, 2026
Primary completion
Sep 14, 2032
Study completion Sep 14, 2032
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Feb 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to provide continued access to the study treatment for participants from previous ViiV Healthcare studies who are still benefiting from it and do not have local access after completing the parent study. This continued access will also allow further collection of safety data. Eligible participants are those who completed a ViiV Healthcare-sponsored or collaborative parent study and are currently experiencing clinical benefit. The Sponsor will periodically review the study to consider other treatment access options.
Conditions
- HIV Infections
Interventions
FostemsavirDrug
Participants receive oral tablets with the dosages depending on the weight of the participants.
Dolutegravir (DTG)/ Lamivudine (3TC)Drug
Participants receive oral tablets with the dosages depending on the weight of the participants.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants who discontinue the study intervention and the reason for discontinuationTime frame: Throughout the study period (from rollover visit at Day 1 until the end of study/withdrawal visit)
- Number of participants with serious adverse events (SAE)Time frame: Throughout the study period (from rollover visit at Day 1 until the end of study /withdrawal visit)
- Number of participants with adverse events of special interest (AESI)Time frame: Throughout the study period (from rollover visit at Day 1 until the end of study /withdrawal visit)
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Bucharest, Romania · Recruiting
GSK Investigational Site
Gauteng, South Africa · Recruiting
GSK Investigational Site
Johannesburg, South Africa · Recruiting
GSK Investigational Site
Johannesburg, South Africa · Recruiting
GSK Investigational Site
Durban, KwaZulu-Natal, South Africa · Recruiting
GSK Investigational Site
Jouberton, Matlosana, South Africa · Recruiting
GSK Investigational Site
Kampala, Uganda · Recruiting
GSK Investigational Site
Kampala, Uganda · Recruiting
GSK Investigational Site
Kampala, Uganda · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.